Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma

 Abstract

A major focus of melanoma research continues to be the search for genes/proteins that may be suitable targets for molecular therapy of primary and metastatic melanoma. In line with this effort, the objective of the study presented herein was to determine whether interfering with cell cycle progression and in particular, the expression and function of select cyclin-dependent kinases, would impair the biological features of advanced melanoma. We provide data, which document that unlike nevi and melanoma in situ, primary and metastatic melanomas express high levels of CDK2, CDK1, and CDK5. Furthermore, we present the results of in vitro and preclinical in vivo studies, which demonstrate that treatment with a small-molecule cyclin-dependent kinase inhibitor that selectively blocks the function of CDK2, CDK5, CDK1, and CDK9, leads not only to inhibition of melanoma cell proliferation and apoptosis of melanoma cells, but also impairs the growth of human melanoma xenografts.

Full Text Options
Article
Metrics
 Share
 Full Text
 Info
Pages
977 - 988
doi
10.4161/cc.10.6.15079
Type
Report
 Metrics
 Cite This Article
 Permissions
 Permissions
 Reprints
Expression analysis and molecular targeting of cyclin-dependent kinases in advanced melanoma